154 related articles for article (PubMed ID: 15928309)
21. Cox-2 inhibitors: still no decisive action.
Prescrire Int; 2005 Jun; 14(77):102. PubMed ID: 15981408
[TBL] [Abstract][Full Text] [Related]
22. [Are COX-2 inhibitors a risk factor for cardiovascular disease?].
John S; Schmieder RE
Dtsch Med Wochenschr; 2002 Jan; 127(4):156-9. PubMed ID: 11807660
[No Abstract] [Full Text] [Related]
23. Erectile dysfunction induced probably by celecoxib.
Dhikav V; Gupta S; Anand KS
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):211-2. PubMed ID: 18236511
[No Abstract] [Full Text] [Related]
24. Coxib medications to be handled with care.
Misak A
CMAJ; 2005 Feb; 172(3):330. PubMed ID: 15615922
[No Abstract] [Full Text] [Related]
25. Valdecoxib: cutaneous and vascular risks.
Prescrire Int; 2005 Apr; 14(76):63. PubMed ID: 15877326
[No Abstract] [Full Text] [Related]
26. COX-2 inhibitors and the heart: putting risk in perspective.
Bobadilla RV; Barnett EM; Randels CL
Adv Nurse Pract; 2005 Nov; 13(11):48-50. PubMed ID: 16295003
[No Abstract] [Full Text] [Related]
27. COX-2 selective drugs and cardiovascular risks: same data but discrepant conclusions?
Bannwarth B
Expert Opin Drug Saf; 2006 Jan; 5(1):1-2; author reply 1-2. PubMed ID: 16370948
[No Abstract] [Full Text] [Related]
28. Side effects of conventional nonsteroidal anti-inflammatory drugs and celecoxib: more similarities than differences.
Stöllberger C; Finsterer J
South Med J; 2004 Feb; 97(2):209. PubMed ID: 14982279
[No Abstract] [Full Text] [Related]
29. FDA ponders future of NSAIDs: Pfizer reluctantly withdraws Bextra.
Young D
Am J Health Syst Pharm; 2005 May; 62(10):997, 1000. PubMed ID: 15901579
[No Abstract] [Full Text] [Related]
30. COX-2 inhibitors. Understanding recent concerns.
Mayo Clin Health Lett; 2002 Oct; 20(10):6. PubMed ID: 12425271
[No Abstract] [Full Text] [Related]
31. [Adverse effects of NSAID are insidious. No pain--despite life threatening gastric hemorrhage].
MMW Fortschr Med; 2002 Sep; 144(37):55. PubMed ID: 12380342
[No Abstract] [Full Text] [Related]
32. Letter by Cen regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas".
Cen YY
Circulation; 2007 Mar; 115(12):e348; author reply e349. PubMed ID: 17389275
[No Abstract] [Full Text] [Related]
33. [Current EULAR data on valdecoxib. New study results of gastrointestinal safety and "cost effectiveness"].
Kellner H
Krankenpfl J; 2004; 42(5-6):185. PubMed ID: 15527245
[No Abstract] [Full Text] [Related]
34. [Progress in therapy of rheumatism. New coxib works especially fast].
MMW Fortschr Med; 2003 Jun; 145(23):58. PubMed ID: 12854230
[No Abstract] [Full Text] [Related]
35. [COX 2 inhibitors--a further step back].
Slørdal L; Evensen S; Spigset O
Tidsskr Nor Laegeforen; 2005 Apr; 125(8):1046. PubMed ID: 15852094
[No Abstract] [Full Text] [Related]
36. Parecoxib, valdecoxib, and cardiovascular risk.
Furberg CD; Psaty BM; FitzGerald GA
Circulation; 2005 Jan; 111(3):249. PubMed ID: 15655125
[No Abstract] [Full Text] [Related]
37. Celecoxib and CVS risk--lessons from the APC and PreSAP studies.
Armstrong DJ
Rheumatology (Oxford); 2007 Apr; 46(4):561-2. PubMed ID: 17132690
[No Abstract] [Full Text] [Related]
38. [Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases].
Guo ZR
Yao Xue Xue Bao; 2005 Nov; 40(11):967-9. PubMed ID: 16499077
[No Abstract] [Full Text] [Related]
39. [Pain therapy in rheumatism. After 65 years of age coxibs are the best choice].
MMW Fortschr Med; 2003 Oct; 145(42):60. PubMed ID: 14655447
[No Abstract] [Full Text] [Related]
40. [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
Bolten WW; Reiter S;
Z Rheumatol; 2005 May; 64(4):286-9. PubMed ID: 15909092
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
